https://www.thebodypro.com/author/barbara-jungwirth

Latest by Barbara Jungwirth

Promo Image
News

This Week in HIV Research: Many Black MSM on PrEP Are Already Positive

High HIV prevalence among black MSM on PrEP; substance use reduction lessens depressive symptoms; correlations between pain symptoms and age; the impact of seroconversion and antiretroviral therapy on risk behaviors.

Urvi Parik, Ph.D., at the HIV Research for Prevention 2018 conference
Women

Dapivirine Vaginal Ring for PrEP Does Not Lead to Drug Resistance

Use of the dapivirine vaginal ring for pre-exposure prophylaxis (PrEP) does not lead to resistance mutations in women who seroconvert, Urvi Parikh, Ph.D., reported at the HIV Research for Prevention 2018 conference.

Promo Image
News

This Week in HIV Research: How Should We Measure Success?

The case for a new measurement of HIV treatment success; PrEP and HIV incidence in Australia; benefits of moderate exercise among older people with HIV; CD4 recovery rates after long-term viral suppression.

Promo Image
News

This Week in HIV Research: The PrEP Sex/Race Gap

PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.

Daniel J. Stieh, Ph.D.

Successful Trial of Quadrivalent Mosaic HIV Vaccine Paves Way for Larger Study in Southern Africa

A quadrivalent mosaic HIV vaccine induced greater immune responses on a variety of assays and against several HIV clades than its trivalent equivalent, as reported at the 2018 HIVR4P conference.

Promo Image
News

This Week in HIV Research: Gender Disparities Among the Formerly Incarcerated

Post-incarceration HIV outcomes worse among women; no drug resistance despite apparent PrEP failure; cost-efficacy of adherence self-management; additional cancers in HIV-positive cancer survivors.

Promo Image
News

This Week in HIV Research: A New Frontier in Organ Transplantation

HIV-positive donor, HIV-negative recipient; continuum of care after incarceration in U.S.; reduced bone mineral density among men with HIV under 50; discouraging anti-inflammatory findings for an antiplatelet agent.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo)
News

Fixed-Dose Doravirine Combination Non-Inferior in Treatment-Experienced Patients

Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...

Promo Image
News

This Week in HIV Research: The Case for Pre-Pregnancy Treatment

The benefits of pre-pregnancy HIV treatment initiation for mothers-to-be; HIV diagnoses rise among young U.S. MSM; cost effectiveness of PrEP for heterosexual women; methotrexate and arterial function.

Promo Image
News

This Week in HIV Research: Food, It Does a Body Good

How food insecurity feeds inflammation; racial disparities in HPV16 prevalence; how HIV meds affect pre-existing neurocognitive impairment; central nervous system inflammation in the setting of HIV treatment success.